Johnson & Johnson and Merck & Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting ...

Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...

Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...

Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer ...

Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...

Merck reported good news Tuesday on a more convenient version of its cancer drug Keytruda, a reassuring sign following ...

Warren Buffett was a net seller of stocks for the eighth consecutive quarter in Q3. Berkshire initiated new positions in only ...

The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Johnson & Johnson and Merck are laying off workers in China, according to a story from Bloomberg which cites reports from ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...